CAJ | 학술논문

大量研究表明，EGFR信号通路与放疗抵抗相关，许多恶性肿瘤高度表达EGFR。 EGFR阻断成为放疗增敏的途径之一。作为第一个由中国和古巴合作研制的EGFR单克隆抗体，尼妥珠单抗有其独特的临床特性，其联合放疗在头颈部肿瘤、食管癌和高级别脑胶质瘤等肿瘤中得到了广泛的研究及探索，本文就尼妥珠单抗放疗增敏的研究现状及进展做一综述。
대량연구표명，EGFR신호통로여방료저항상관，허다악성종류고도표체EGFR。 EGFR조단성위방료증민적도경지일。작위제일개유중국화고파합작연제적EGFR단극륭항체，니타주단항유기독특적림상특성，기연합방료재두경부종류、식관암화고급별뇌효질류등종류중득도료엄범적연구급탐색，본문취니타주단항방료증민적연구현상급진전주일종술。
With data support from abundant research ,epithelial growth factor receptor ( EGFR) signaling pathway is associated with radiotherapy resistance .EGFR inhibition has become one of methods to increase radio-sensitivity.As the first EGFR monoclonal antibody developed by China and Cuba ,nimotuzumab demonstrates its distinct clinical characteristics and has been extensively explored in head and neck cancer , esophageal cancer , high grade glioma .This article mainly reviews the present situation and recent advances on the radiosensitivity re -search of nimotuzumab .